PFIZER INCPFE
PFIZER INC Financial Overview 2020–2024
Pfizer’s revenue collapsed from a pandemic peak of $100.3 billion in FY2022 to $58.5 billion in FY2023, a 42% decline that forced a rapid strategic overhaul. The company has since pivoted capital allocation toward high-growth verticals like oncology and weight loss, executing the $43 billion acquisition of Seagen and the $7.0 billion purchase of Metsera in late 2025. This aggressive M&A strategy aims to fill the growth void left by plummeting demand for COVID-19 products, replacing volatile vaccine income with a diversified pipeline of cancer and cardiometabolic therapies.
Despite the massive contraction from pandemic highs, the company’s financial floor has risen, with total revenue expanding from $41.9 billion in FY2020 to $63.6 billion in FY2024. Execution on this new portfolio is mixed but improving; while legacy Comirnaty sales plunged 87% operationally in Q2 2024, the Vyndaqel family surged 33% in Q1 2025. To protect margins during this transition, management expanded its cost realignment program, targeting $5.7 billion in net savings by 2027. Profitability has stabilized significantly following these moves: Pfizer reported $3.54 billion in net income for Q3 2025, a sharp recovery from the $2.38 billion net loss incurred in Q3 2023 during the height of its inventory write-offs.
Recent Developments (Q2 and Q3 2025)
Pfizer’s transition delivered mixed top-line results recently, with revenue rising 10% to $14.7 billion in Q2 2025 before slipping 6% to $16.7 billion in Q3 2025. Despite sales volatility caused by declining Paxlovid volumes, aggressive efficiency measures drove a 21% reduction in cost of sales during the third quarter, helping lift year-to-date net income to $9.42 billion. The oncology portfolio provided a crucial offset to vaccine headwinds, led by Padcev, which surged 32% in the first half of the year. To support its pipeline expansion, including a $1.25 billion licensing agreement with 3SBio and the integration of Metsera, the company completed a $6.75 billion debt offering in November 2025.
Bulls point to improved profitability and strong non-COVID product launches as proof of a successful pivot, while bears worry that reliance on expensive M&A adds significant execution risk. The stock traded at 17.2x earnings as of November 3, 2025.
What to watch: MET-097i clinical trial milestones; full-year 2026 revenue guidance.
Rev
$63.63B
FY2024
NI
$8.03B
FY2024
EPS
$1.42
FY2024
OCF
$12.74B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
PFIZER INC 8-K Report, Financial Results (Feb 3, 2026)
Pfizer Inc. (PFE) has filed an 8-K report on February 3, 2026, to announce its financial results for the fourth quarter of 2025. The report primarily references a press release, filed as Exhibit 99, which contains the detailed financial performance for the quarter. Investors should refer to this press release for comprehensive information regarding Pfizer's operational and financial condition as of the end of 2025. This filing serves as a notification of the release of Q4 2025 earnings and is crucial for understanding the company's recent performance. While the 8-K itself is brief, it directs stakeholders to the accompanying press release for substantive details on revenue, profitability, and any forward-looking statements or guidance provided by the company. Investors are advised to consult Exhibit 99 for a complete picture of Pfizer's financial standing and its outlook.
PFIZER INC 8-K Report, Regulation FD Disclosure (Dec 16, 2025)
Pfizer Inc. (PFE) has filed an 8-K report detailing updated financial guidance. The company announced revised full-year 2025 revenue guidance and provided its full-year 2026 guidance, while reaffirming all other components of its 2025 financial outlook. This update is being communicated to investors via a press release filed as an exhibit to this report. Investors should pay close attention to the specifics of the revenue revision for 2025 and the outlook for 2026 as provided in the accompanying press release. While other 2025 guidance components remain unchanged, the revenue adjustments could signal shifts in market dynamics or product performance. The 2026 guidance will offer a forward-looking perspective on Pfizer's expected financial trajectory.
PFIZER INC 8-K Report, Corporate Update (Nov 21, 2025)
Pfizer Inc. (PFE) announced the successful completion of a significant public offering of various debt securities on November 21, 2025. The offering comprised an aggregate principal amount of $6.75 billion across multiple tranches, including Floating Rate Notes due 2027 and fixed-rate notes maturing between 2027 and 2065 with coupon rates ranging from 3.875% to 5.700%. This substantial capital raise was executed under Pfizer's existing shelf registration statement. This offering indicates Pfizer's proactive approach to managing its capital structure and potentially funding ongoing operations, research and development, or strategic initiatives. The diverse maturity dates and interest rate structures of the notes suggest a strategy to diversify its debt profile and optimize borrowing costs. Investors should note the total size of the issuance and the specific terms of each note series to understand Pfizer's current debt obligations and its financial strategy.
PFIZER INC 8-K Report, Corporate Update (Nov 13, 2025)
Pfizer Inc. announced the successful completion of its acquisition of Metsera, Inc. for an enterprise value of approximately $7.0 billion. This strategic move signifies Pfizer's expansion into the obesity and metabolic disease market, a key growth area. The acquisition was executed through a merger agreement, with Metsera shareholders receiving $65.60 in cash per share at closing. In addition to the upfront cash payment, Metsera shareholders are eligible to receive contingent value rights (CVRs) worth up to an additional $20.65 per share. These CVRs are tied to the achievement of specific developmental and regulatory milestones related to Metsera's pipeline, notably its GLP-1 receptor antagonist and amylin analog drug candidates. Investors should closely monitor the progress of MET-097i and MET-233i, as their successful advancement could represent significant future value creation for Pfizer.
PFIZER INC 8-K Report, Financial Results (Nov 4, 2025)
Pfizer Inc. (PFE) has filed a Form 8-K on November 4, 2025, to report its financial results for the third quarter of 2025. The key information is contained within the press release furnished as Exhibit 99, which details the company's operational and financial performance for the period. Investors should refer to this press release for specific figures regarding revenue, earnings, and any forward-looking guidance provided by the company. While the 8-K itself is a procedural filing, the accompanying press release is the critical document for understanding Pfizer's recent financial health and outlook. The filing notes that the information furnished is not deemed "filed" for Section 18 purposes, but it is incorporated by reference into the press release, making it the primary source for investor analysis. Investors are encouraged to review the full press release for a comprehensive understanding of Pfizer's third-quarter 2025 performance.
View all 8-K filings →